Abstract
PURPOSE: Activated recombinant factor VII (FVIIa) (NovoSeven, NovoNordisk, Copenhagen, Denmark) is successful at controlling perioperative hemorrhage in hemophiliacs. Its efficacy in cardiac surgery, however, is less documented and has primarily been investigated as rescue therapy in patients with intractable coagulopathy despite conventional treatment with massive blood products. We proposed utilizing FVIIa as first line therapy in cardiac surgery patients with low platelet counts in an attempt to reduce blood product usage.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call